About Medistem
Medistem is a Healthcare company based in San Diego (United States) founded in 2005, and was acquired by Precigen in December 2013. Stem-cell-based therapies to stimulate new blood vessel formation. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells. Its competitors include ViaCyte, Neurona Therapeutics and DiscGenics; 3 of its 3 listed competitors have raised funding.
Company details
MediStem is focussed on developing adult stem cell-based therapeutic products. It has developed ERC-124, a stem cell product derived from the endometrium which can stimulate new blood vessel formation and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These properties claims to have potential applications for treatment of Critical Limb Ischemia (CLI), Congestive Heart Failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. In December 2013, Intrexon Corporation acquired Medistem for 26M.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website medisteminc.com
- Social LinkedIn X
- Acquired by Precigen (Dec 2013)
Investors in Medistem
Medistem has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Precigen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases | 1998 | precigen.com | Germantown, United States |
Investor details for Medistem
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Medistem
2 dated milestones of Medistem across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Medistem is founded.
- Exit Acquired by Precigen.
Competitors of Medistem
Medistem has 3 listed competitors in our database, 3 of them funded. They include ViaCyte, Neurona Therapeutics and DiscGenics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viacyte.com | 1999 | San Diego, United States | $389.03M | 126 | Cell therapy for diabetes is developed from stem cells. | |
| neuronatherapeutics.com | 2008 | San Francisco, United States | $417.69M | 67 | Cell-based therapies are developed for intractable neurological diseases. | |
| discgenics.com | 2008 | Salt Lake, United States | $65.84M | 45 | Tissue engineering company utilizing a proprietary stem technology to treat degenerative disc disease. |
Detailed competitors of Medistem
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as Medistem (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Medistem
Medistem was founded in 2005.
Medistem is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
MediStem is focussed on developing adult stem cell-based therapeutic products. It has developed ERC-124, a stem cell product derived from the endometrium which can stimulate new blood vessel formation and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These properties claims to have potential applications for treatment of Critical Limb Ischemia (CLI), Congestive Heart Failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. In December 2013, Intrexon Corporation acquired Medistem for 26M.
Medistem's top competitors include Neurona Therapeutics, DiscGenics and ViaCyte.
Medistem has 1 investor. Key investors include Precigen.
Yes. Medistem was acquired by Precigen in December 2013.